Publications by authors named "J Schnorbach"
Article Synopsis
- * A study of 218 OMD NSCLC patients showed that those with fewer metastases and female patients had significantly longer overall survival rates, with a median OS of 27.8 months and a 5-year survival rate of 29%.
- * Patients who underwent comprehensive local ablation combined with systemic therapy experienced improved recurrence-free survival, highlighting that adding immunotherapy could enhance outcomes, indicating a potential for a curative approach.
Background: Predictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information.
Methods: The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations.
Article Synopsis
- The study investigated if advanced molecular profiling can forecast the emergence of the T790M mutation in EGFR, a common resistance factor in non-small cell lung cancer (NSCLC) after treatment with EGFR inhibitors.
- The research utilized whole exome sequencing on tumor samples from NSCLC patients to determine genetic and clinical characteristics, noting that these factors had no significant correlation with the T790M mutation's presence.
- Instead, complex biomarkers like tumor mutational burden and specific mutation signatures were significantly correlated with the mutation and could individually predict its development, achieving a prediction accuracy of 72-77%, despite limited case numbers affecting the results' robustness.
Background: Brain metastases (BMs) are a key challenge in the management of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC), but prognostic scores are complicated or rely on data before the era of tyrosine kinase inhibitors (TKIs). This study aimed to validate the novel ALK-Brain Prognostic Index (ALK-BPI), which was originally proposed based on 44 TKI-treated ALK+ NSCLC patients from Karolinska University Hospital, using an external clinical cohort.
Patients And Methods: TKI-treated ALK+ NSCLC patients with BM from Heidelberg (n = 82, cohort 1) were retrospectively analyzed alone and together with the original Karolinska cohort (n = 126, cohort 2).
Aims: Co-morbid atrial fibrillation (AF) increases both mortality and N-terminal pro brain natriuretic peptide (NT-proBNP) concentrations in patients with chronic heart failure (CHF). It is unclear whether AF worsens prognosis independently from NT-proBNP concentrations. If AF was an independent risk factor, NT-proBNP levels for outcome prediction would need to be adjusted in patients with AF.
View Article and Find Full Text PDF